Relmada Therapeutics Prepares for Q4 2024 Financial Discussion

Relmada Therapeutics to Discuss Fourth Quarter Financials

Relmada Therapeutics, Inc. (Nasdaq: RLMD), a pioneering biotechnology firm, is set to host an important conference call and webcast to share their fourth-quarter financial results and recent advancements in their programs. This event will take place on a day that is significant for the company as they reflect on their progress and outline future directions.

Conference Call and Webcast Details

The conference call is scheduled for a Thursday afternoon, an ideal time for investors and stakeholders to join and hear directly from the company's leadership. The call is expected to start promptly at 4:30 PM Eastern Time.

How to Participate

For those who wish to dial in, there are specific numbers available. Participants in the United States can call 1-877-407-0792, while international attendees can reach the conference at 1-201-689-8263. The conference ID for this event is 13751458, ensuring your entry into the call.

Webcast Access

For convenient access to the discussion, a webcast will also be available. Participants can easily join online to hear the live presentation and reflect on the opportunities presented by the company.

Webcast Replay Availability

For those unable to attend the live discussion, a replay of the webcast will be accessible afterward in the Investors section of Relmada's official website. This feature allows stakeholders to stay updated on the company's performance and strategic plans.

Company Overview: Relmada Therapeutics

Relmada Therapeutics is dedicated to transforming the landscape of treatment options for patients. As a clinical-stage biotech organization, they focus on developing groundbreaking therapies aimed at providing significant clinical benefits to those in need.

Innovative Programs Under Development

One of the company's lead investigational programs, NDV-01, is currently in a Phase 2 study targeting High-Grade Non-Muscle Invasive Bladder Cancer. This program represents a crucial step in finding effective treatments for patients suffering from this condition, showcasing Relmada's commitment to innovation.

Advancements in Compulsion-Related Disorders

In addition, preparations are in progress to advance Relmada’s investigational program, sepranolone. This program is ready to enter Phase 2b trials and focuses on compulsion-related disorders, including Tourette’s Syndrome. These efforts illustrate the company's proactive approach in addressing various challenging health issues.

Stay Informed with Relmada Therapeutics

The company encourages everyone to stay informed about their progress by regularly visiting their website and accessing investor resources. This way, stakeholders can keep abreast of new developments and planned releases that may impact their investments.

Contacting Relmada Therapeutics

If you have any inquiries, they have dedicated contacts for investor relations and media inquiries. Brian Ritchie from LifeSci Advisors is the primary contact for investor-related questions, reachable via email. Additionally, media inquiries can be directed to the corporate communications team via another dedicated email.

Frequently Asked Questions

What time is the fourth-quarter financial results conference call?

The conference call will take place at 4:30 PM ET on Thursday.

How can I access the webcast of the conference call?

You can access the webcast through the official Relmada Therapeutics website.

What is Relmada Therapeutics focusing on in their programs?

Relmada focuses on innovative therapies for conditions such as High-Grade Non-Muscle Invasive Bladder Cancer and compulsion-related disorders.

Who can I contact for investor-related inquiries?

Brian Ritchie at LifeSci Advisors is the contact for investor inquiries.

Where can I find more information about Relmada Therapeutics?

More information can be found on Relmada Therapeutics' official website, where updates and resources are regularly posted.

About The Author

My name is Dylan Bailey, and I am 28 years old. I am an author and an expert on the stock market who specializes in publicly traded companies. Early fascination with the stock market inspired me to seek a finance degree and then delve deeply into the world of stocks. I have developed over the years my abilities to spot investment prospects, assess business performance, and analyze market trends.

My books and articles try to help regular investors understand the nuances of the stock market. Anyone can, in my opinion, make wise investment choices and succeed financially if they have the correct information and resources. In my writing, I combine in-depth research with practical insights and advice that can be put into action. This is done with the intention of assisting readers in navigating the constantly shifting landscape of publicly traded companies.

In addition to writing, I also host webinars and workshops, where I give presentations and share my knowledge with a wider audience. I also write for top financial journals and show up as a guest analyst on financial news shows. I like to travel, spend time with my family, and keep active by playing different sports when I'm not buried in market research.

My goal is to enable people to choose wisely and consciously in their investments, so taking charge of their financial futures. By my work, I hope to create a community of informed and self-assured investors prepared to take advantage of the chances presented by the stock market.

Contact Dylan Bailey privately here. Or send an email with ATTN: Dylan Bailey as the subject to contact@investorshangout.com.

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.